Outcomes of membranous and proliferative lupus nephritis – analysis of a single-centre cohort with more than 30 years of follow-up
Filipa Farinha(Instituto Politécnico de Santarém), Anisur Rahman(University College London), Thomas McDonnell(University College London), David Isenberg(Regenerative Medicine Institute), Daniel G Oliveira(Centro Hospitalar do Porto), Ruth J. Pepper(University College Hospital)
Cited by 27
Related Papers
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
|The Lancet Haematology|2016|404
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
|Lara D. Veeken|2003|367
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
|Annals of the Rheumatic Diseases|2016|355